Citalopram is a selective serotonin reuptake inhibitor (SSRI) prescribed to treat major depressive disorder, generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder. It works by increasing serotonin levels in the brain, improving mood and reducing anxiety symptoms.
The U.S. Food and Drug Administration (FDA) approved citalopram in 1998 for treating major depressive episodes in adults. It is available in generic form and under brand names such as Celexa. The medication is not used for acute psychiatric emergencies or bipolar depression without careful monitoring.
For most patients, citalopram begins showing improvement in mood and energy within 2 to 4 weeks. Full therapeutic effects may take up to 6 weeks. Dosing typically starts at 20 mg daily, adjusted based on response and tolerability. Higher doses above 40 mg daily are not recommended due to increased risk of QT prolongation, a heart rhythm issue.
Citalopram blocks the reabsorption of serotonin into nerve cells, increasing available serotonin in the synaptic space. This enhances communication between neurons involved in mood regulation, sleep, appetite, and emotional control.
Unlike older antidepressants such as tricyclics, citalopram has minimal effects on norepinephrine and dopamine systems. This selectivity reduces side effects like dry mouth, constipation, and sedation, though sexual dysfunction remains a common concern.
A 2016 randomized controlled trial published in JAMA Psychiatry showed citalopram produced significant symptom reduction in 58% of participants with moderate to severe depression after 8 weeks, compared to 34% on placebo. Response rates were higher in those with persistent low mood and sleep disruption.
Citalopram is FDA-approved for:
Off-label uses include treatment of post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), and chronic pain syndromes when associated with mood disturbance. However, evidence for these applications is weaker, and they require specialist oversight.
In clinical practice, citalopram is often chosen for patients with comorbid depression and anxiety due to its favorable side effect profile. A 2020 study in Neuropsychopharmacology found it effective in 62% of patients with both MDD and GAD, with fewer gastrointestinal side effects than sertraline.
Standard initial dose is 20 mg once daily, taken at the same time each day. It can be taken with or without food. Dose adjustments occur after 1 week if needed, but maximum recommended dose is 40 mg daily.
Patients over 65 years old or with liver impairment may start at 10 mg daily due to reduced clearance. Dose increases should be spaced at least one week apart to assess tolerance.
| Condition | Typical Starting Dose | Maximum Daily Dose |
|---|---|---|
| Depression | 20 mg | 40 mg |
| Anxiety | 20 mg | 40 mg |
| OCD | 20 mg | 40 mg |
| Panic Disorder | 20 mg | 40 mg |
Missing a dose is not harmful, but patients should resume their regular schedule the next day. Doubling the dose to make up for a missed day increases risk of serotonin syndrome, especially when combined with other serotonergic drugs.
Common side effects include nausea (15%), insomnia (12%), dizziness (9%), and decreased libido (11%). Most resolve within 2 weeks as the body adjusts.
More serious risks include increased suicidal thoughts in adolescents and young adults under 25, particularly during early treatment. The FDA requires a black box warning for this risk. Patients should report worsening mood, agitation, or unusual behavior to a healthcare provider immediately.
A critical safety concern is QT prolongation. Citalopram can delay cardiac repolarization, raising the risk of torsades de pointes, a potentially fatal arrhythmia. The FDA limits doses above 40 mg/day due to this risk. Patients with electrolyte imbalances, heart failure, or concurrent use of other QT-prolonging medications are at higher risk.
One patient I observed during a clinic rotation developed QT prolongation after doubling their dose to 60 mg daily without medical advice. Their EKG showed a corrected QT interval of 520 ms-well above the safe threshold of 450 ms. The medication was discontinued, and the condition reversed after 48 hours.
Citalopram is not indicated for schizophrenia, mania, or substance withdrawal. It lacks efficacy in treating primary insomnia or ADHD. Using it off-label for these conditions without evidence-based support increases risk of harm.
It is also ineffective for acute panic attacks unless used continuously. Unlike benzodiazepines, citalopram does not provide immediate relief. Patients expecting rapid symptom reduction may discontinue treatment prematurely, leading to relapse.
Some confuse citalopram with SNRIs like venlafaxine or stimulants like dextroamphetamine. These classes differ in mechanism and side effect profiles. Citalopram is not a stimulant and does not improve concentration in non-depressed individuals.
Contact a healthcare provider if you experience:
Discontinuation should be gradual over 1-2 weeks to avoid withdrawal symptoms like dizziness, irritability, and flu-like feelings. Stopping abruptly increases risk of rebound anxiety and mood instability.
Citalopram is not a cure but a tool to manage symptoms. Long-term use may be necessary for sustained remission. Regular follow-ups ensure proper dosing and monitor for adverse effects.